Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

December 31, 1998

Primary Completion Date

January 31, 2001

Conditions
Brain and Central Nervous System Tumors
Interventions
DRUG

temozolomide

Trial Locations (24)

1070

Hopital Universitaire Erasme, Brussels

1090

Academisch Ziekenhuis der Vrije Universiteit Brussel, Brussels

1093

Instituto Portugues de Oncologia de Francisco Gentil, Lisbon

5001

Kantonspital Aarau, Aarau

13385

CHU de la Timone, Marseille

35128

Azienda Ospedaliera di Padova, Padova (Padua)

54035

CHU de Nancy - Hopital Neurologique, Nancy

59037

Centre Hospitalier Regional de Lille, Lille

B-3000

U.Z. Gasthuisberg, Leuven

06002

Hopital Pasteur, Nice

06189

Centre Antoine Lacassagne, Nice

F-94805

Institut Gustave Roussy, Villejuif

D-96049

Nervenklinik Bamberg, Bamberg

D-12200

Universitaetsklinikum Benjamin Franklin, Berlin

DOH-9-3053

Klinikum der Universitat Regensburg, Regensburg

00161

Istituti Fisioterapici Ospitalieri - Roma, Rome

NL-6252 HB

University Medical Center Nijmegen, Nijmegen

3075 EA

Rotterdam Cancer Institute, Rotterdam

3508 GA

Academisch Ziekenhuis Utrecht, Utrecht

833 03

Postgraduate Medical Institute, Bratislava

CH-4031

University Hospital, Basel

CH-3010

Inselspital, Bern, Bern

CH-1011

Centre Hospitalier Universitaire Vaudois, Lausanne

EH4 9NQ

Western General Hospital, Edinburgh

All Listed Sponsors
lead

European Organisation for Research and Treatment of Cancer - EORTC

NETWORK

NCT00003731 - Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors | Biotech Hunter | Biotech Hunter